The coincidence of schizophrenia and Parkinsonism: some neurochemical implications.
The hypothesis has recently been advanced that increased activity of central dopaminergic mechanisms underlies the symptomatology of the schizophrenias. The evidence that dopaminergic transmission in the corpus striatum is impaired in Parkinson's disease suggests that observations on the relationship between Parkinson's disease and  schizophrenia may illuminate the patholophysiology of the latter disease. Four cases are reported in which an illness with schizophrenic features developed in the setting of longstanding Parkinson's disease; attention is drawn to earlier reports of schizophrenic illnesses occurring as postencephalitic sequelae in the presence of a parkinsonian syndrome. These observations appear to conflict with the view that increased dopamine release in the striatum is necessary for the expression of schizophrenic psychopathology, but do not exclude the possibility that increased transmission may occur at other dopaminergic sites in the brain, for example the nucleus accumbens, tuberculum olfactorium or cerebral cortex. Similarly the dopamine receptor blockade hypothesis of the therapeutic effects of neuroleptic drugs cannot be maintained with respect to an action in the striatum in view of the differences between the actions of thioridazine and chlorpromazine in this structure, but may be tenable for actions at extra-straital sites.
D000368:Aged; D003702:Delusions / Q000503:physiopathology; D004298:Dopamine / Q000502:physiology*; D005260:Female; D006212:Hallucinations / Q000503:physiopathology; D006801:Humans; D008875:Middle Aged; D010301:Parkinson Disease, Postencephalitic / Q000188:drug therapy / Q000503:physiopathology*; D010302:Parkinson Disease, Secondary / Q000150:complications; D011352:Procyclidine / Q000008:administration & dosage; D011954:Receptors, Dopamine / Q000187:drug effects; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D012565:Schizophrenic Psychology; D014282:Trihexyphenidyl / Q000008:administration & dosage
D011954:Receptors, Dopamine; D014282:Trihexyphenidyl; D011352:Procyclidine; D004298:Dopamine